Search

1366 Result(s)
Sort by

Partnership-with-clicktherapeutics

Partnership-with-clicktherapeutics

Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Their dogs are their world

Their dogs are their world

Corporate social responsibility in Brazil: Volunteer work and animal healthcare donations for homeless people and their pets.
EMPRISE

EMPRISE

Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Cooperation with The Defeat-NCD Partnership

Cooperation with The Defeat-NCD Partnership

Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
The big, the bold, and the few

The big, the bold, and the few

In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
The GPP Forum

The GPP Forum

The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
The status of schizophrenia care

The status of schizophrenia care

A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Connect the Docs

Connect the Docs

Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.